EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSUMAG00000009514
Gene Symbol: PIK3R2
4 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSUMAG00000023883
Gene Symbol: PIK3R3
4 Cross references
274 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSUMAG00000018881
Gene Symbol: PLA2G5
4 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSUMAG00000005118
Gene Symbol: PLA2G7
4 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSUMAG00000004541
Gene Symbol: PLA2G10
2 Cross references
249 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSUMAG00000020039
Gene Symbol: GART
4 Cross references
215 Possible Orthologues:

Plasminogen

Ensembl ID : ENSUMAG00000011793
Gene Symbol: PLG
3 Cross references
240 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSUMAG00000025567
Gene Symbol: PLAT
4 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSUMAG00000011170
Gene Symbol: PTAFR
4 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSUMAG00000003589
Gene Symbol: PDGFRA
4 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSUMAG00000004358
Gene Symbol: PDGFRB
4 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSUMAG00000014423
Gene Symbol: PDGFB
2 Cross references
261 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).